Updated Jul 16, 2026
Skvarka Jan has filed 2 SEC Form 4 filings across 2 companies in the last 90 days.
Skvarka Jan is an individual referenced in Monte Rosa Therapeutics, Inc. SEC filings as of June 12, 2026. The available context identifies the person in connection with the company, but the provided excerpt does not specify a title, role, or detailed biographical background. No additional public biographical information is confirmed from the context provided.
| Role | Director |
|---|---|
| Notability | 25/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-18 | ZNTL | Zentalis Pharmaceuticals, Inc. | A — Grant or award | 57.1K | $0.00 |
Skvarka Jan is an individual referenced in Monte Rosa Therapeutics, Inc. SEC filings as of June 12, 2026. The available context identifies the person in connection with the company, but the provided excerpt does not specify a title, role, or detailed biographical background. No additional public biographical information is confirmed from the context provided.…
2 primary Form 4 filings in the last 90 days, covering 2 companies.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Skvarka Jan profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.